The anti-doping agency says many sellers use research chemical labels to dodge FDA scrutiny while selling peptides and SARMs.
Recap by typeshit. Post by USADA on X.
A short teaser comparing how well people tolerate the two main GLP-1 ingredients, with the full breakdown behind the link.
Doctors quoted by Men's Journal raise concerns about how much GLP-1 users are paying for add-on supplements each month.
An older explainer sorting the weight loss market into approved medications, telehealth compounded drugs, online gray market peptides and supplements.
Vecchio calls the drugs a fresh start for her life, but Reuters notes the cost came in side effects, including gastrointestinal trouble.
The estimate, shared by M Mohan, starts from about $141 billion in 2025, with North America holding roughly 62% and semaglutide and tirzepatide leading.
Medscape asks if Eli Lilly's experimental triple-acting drug could help patients who stall on current GLP-1 treatments. Few details are given beyond the headline.
Loading…